Warning
Mae'r hysbyseb swydd hon wedi dod i ben ac mae'r ceisiadau wedi cau.
Specialist Clinical Pharmacist – MH Research & Clinical Trials
| Dyddiad hysbysebu: | 10 Mai 2024 |
|---|---|
| Cyflog: | £43,742.00 i £50,056.00 bob blwyddyn |
| Gwybodaeth ychwanegol am y cyflog: | £43742.00 - £50056.00 a year |
| Oriau: | Llawn Amser |
| Dyddiad cau: | 02 Mehefin 2024 |
| Lleoliad: | Warrington, WA2 8WA |
| Cwmni: | NHS Jobs |
| Math o swydd: | Parhaol |
| Cyfeirnod swydd: | C9350-24-0906 |
Crynodeb
To be responsible for implementing the Medicines Management strategy in the Trust and supporting the research and clinical trials pharmacy service in line with national and regulatory requirements.2.To deputise for a higher grade of pharmacist as required3.Participation in screening, dispensing and checking of clinical trial prescriptions, and advising others of Good Clinical Practice (GCP), Good Manufacturing Practice (GMP) and requirements relating to Investigational Medicinal Product (IMP) management.4.To participate in the Trust-wide Out of Hours Medicines Advice Service and seven-day medicine supply service.5.Completing with the support of Pharmacy Technicians, the process of medicines reconciliation following admission or transfer of service users within the trust or for the purposes of research or clinical trials. This involves collating information from patients and carers and liaising with professionals from other healthcare organisations to ascertain presenting complaint, past medical and medication history, working diagnosis and relevant biomedical and psychiatric test results to ensure the safe and effective use of medicines.6.Ensuring that each medicine has an appropriate indication and each diagnosis has appropriate therapy.7.Ensuring that existing therapy is safe to take with, and has not contributed to, the presenting complaint.8.Ensuring that new treatments are compatible with the patients conditions.9.Making recommendations on changes to drug therapy in line with the above.10.Reviewing recommendations in the light of new results and treatment plans.11.Advising on which medications should continue and which should stop, as appropriate.12. Monitoring for adverse drug reactions and submitting yellow cards where appropriate. Reporting adverse events arising from the use of IMP to the trial sponsor and in line with agreed trial procedure 13. Please refer to JD for more information.